ZalVac is a company headquartered in Sweden.
ZalVac AB develops vaccines based on bacterial membrane vesicles to induce robust immunity against multiple strains of bacteria, translating academic research by Birgitta Henriques Normark and Staffan Normark into vaccine candidates.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.